ClinicalTrials.gg
CompletedNCT05674682SeroincidenceUpdated Jan 6, 2023

Seroincidence Study Among Men Who Have Sex With Men and Transgender Women - The ImPrEP Seroincidence Study

An interventional study of HIV testing in HIV Infections, Risk Reduction and Risk Behavior, sponsored by Evandro Chagas National Institute of Infectious Disease. Completed at 2 sites in Brazil. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-06.

Primary conditionHIV SeropositivityRegistry: HIV InfectionsReclassifiedWhy we changed it
Registry
HIV Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
HIV Seropositivity
Why
  1. The study's listed conditions name HIV Seropositivity, a narrower term within HIV Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Evandro Chagas National Institute of Infectious Disease · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 3 years 3 months after the study started (first participant enrolled Oct 2019, registered Jan 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
4,000
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Study summary

PrEP (pre-exposure prophylaxis) is an effective prevention strategy in which HIV-negative individuals take antiretroviral drugs (tenofovir disoproxil fumarate and emtricitabine - TDF/FTC) to reduce HIV acquisition. Clinical studies have shown that the TDF/FTC combination protects MSM and transgender women against HIV infection. According to the PROUD study, PrEP can decrease the risk of HIV infection among MSM by 86% (90% CI 64-96). The international community recognizes that PrEP can be an additional tool in the framework of a combination prevention package for those most at risk of contracting HIV. Data on HIV incidence among MSM and trans women are largely unknown. In Brazil, Mexico and Peru, data on the incidence of HIV among MSM and trans women are very scarce, limited to small cross-sectional studies.Current methods used to determine HIV-1 incidence have many limitations. These methods include mathematical modeling, retrospective calculations of AIDS case reports, age-based prevalence determinations, and prevalence determinations with multiple rounds of longitudinal surveys to estimate HIV incidence, which require numerous assumptions and inputs and can pose additional challenges in the era of expansion of antiretroviral therapy (ART) and increased survival of HIV-1 infected individuals. On the other hand, prospective longitudinal cohort studies of high-risk individuals can be used to estimate incidence; however, they are often labor-intensive, complex, very expensive, difficult to implement in most countries, and have recruitment biases. Laboratory methods can be unbiased and do not require complicated assumptions and case-by-case weighting. The cross-sectional use of Recent HIV Infection Tests (TRIs) based on biomarkers offers, in principle, accessible, reliable and low risk of bias options for estimating incidence.

02

Conditions studied

  • HIV Infections
  • Risk Reduction
  • Risk Behavior
  • Risky Health Behavior
  • STD
  • HIV Seropositivity
  • HIV Infection Primary

Keywords

  • MSM
  • TGW
  • Imprep
  • HIV
03

In context

HIV Seropositivity Reclassified

194 studies on the registry are indexed under HIV Seropositivity; 10 are open to participants now.

This study's enrollment of 4,000 is above the median of 105 across 114 interventional studies indexed under HIV Seropositivity.

Browse HIV Seropositivity studies →

Lead sponsor

Evandro Chagas National Institute of Infectious Disease is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Compared within HIV Seropositivity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is HIV Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • MSM and transgender women
  • aged 18 years or older
  • willingness and ability to sign an form.

Exclusion criteria

Exclusion Criteria:

  • Individuals currently using PrEP, PEP or receiving antiretroviral therapy;
  • Individuals unable to understand the study or who do not agree to sign the consent form;
  • Individuals who are participating in a clinical trial of antiretroviral medication or any product to prevent the acquisition of infection (for example, monoclonal antibodies such as PEP or PrEP)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4,000 participants (actual)

Study arms

  • Other
    Venipuncture or digital puncture for HIV test

    MSM and transgender women aged 18 years or older, willing and able to sign informed consent to accept venipuncture or digital puncture for HIV testing

    Procedure: HIV testing

Interventions

  • ProcedureHIV testing

    venipuncture or digital puncture for HIV testing

06

What researchers measure

Primary outcomes

  1. Identification of recent infections in a given high-risk population (MSM and TGW), including those in defined geographic areas for evaluate epidemics, calibrate models, design and evaluate interventions.

    Blood collected for viral load from those with confirmed HIV infection will be used to distinguish recent HIV-1 infections of long-term infections

    Time frame: 2 years

07

Study locations

2 sites
  • Instituto Nacional de Infectologia Evandro Chagas (Fiocruz)
    Rio de Janeiro, RJ 21040-360, Brazil
  • Instituto Nacional de Infectologia Evandro Chagas/ FIOCRUZ
    Rio De Janeiro, 21040-360, Brazil
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in May 2020, 7 months.

Of 28 non-industry interventional studies with no phase under HIV Seropositivity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 46. This study's 7 months is below that.

Counting every sponsor, half of 29 studies reached it within 23 months; a quarter within 8 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2023
First posted
Jan 6, 2023
StartActual
Oct 1, 2019
Primary completionActual
May 31, 2020
CompletionActual
Jun 30, 2020
Last update
Jan 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05674682
Lead sponsor
Evandro Chagas National Institute of Infectious Disease
Collaborators
Valdiléa Veloso dos Santos, Ph.D., Beatriz Grinzstejn, MD, PhD, Brenda Hoagland, MD, PhD, Celia Landmann Szwarcwald, PhD, Thiago Torres, PhD, Maria Cristina Pimenta, MD, PhD, Marcos Benedetti, MA, Marília Santini Oliveira, Ronaldo Ismério Moreira, PhD, Sandro Nazer Coutinho, Sylvia Lopes Maia Teixeira, PhD, Nilo Martínez Fernandes, PhD, Hamid Vega-Ramírez, MD, MSc, Sérgio Bautista-Arredondo, MD, PhD, René Leyva-Flores, PhD, Helleen Vermandere, Santiago Ávila-Ríos, PhD, Claudia García-Morales, PhD, Carlos Cáceres, MD, MPH, PhD, Kelika A. Konda, PhD, Juan Vicente Guanira, MD, PhD, Giovanni Ravasi, MD, MScPH
Responsible party
Raquel Malaguthi de Souza (Regulatory Affairs Associate, Evandro Chagas National Institute of Infectious Disease) — Principal investigator
First posted
Jan 6, 2023
Start date
Oct 1, 2019
Primary completion
May 31, 2020
Completion
Jun 30, 2020
Last update
Jan 6, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion